Literature DB >> 18502845

Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis.

Julien Haroche, Zahir Amoura, Frédéric Charlotte, Juan Salvatierra, Bertrand Wechsler, Carlos Graux, Nicole Brousse, Jean-Charles Piette.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18502845     DOI： 10.1182/blood-2008-03-148304

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  16 in total

1.  Erdheim-Chester disease: The role of video-assisted thoracoscopic surgery in diagnosing and treating cardiac involvement.

Authors:  Aoife Egan; Dan Sorajja; Dawn Jaroszewski; Farouk Mookadam
Journal:  Int J Surg Case Rep       Date:  2011-12-08

Review 2.  Erdheim-Chester Disease: a comprehensive review of the literature.

Authors:  Roei D Mazor; Mirra Manevich-Mazor; Yehuda Shoenfeld
Journal:  Orphanet J Rare Dis       Date:  2013-09-08       Impact factor: 4.123

3.  A tale of two histiocytic disorders.

Authors:  Filip Janku; Javier Munoz; Vivek Subbiah; Razelle Kurzrock
Journal:  Oncologist       Date:  2013-01-08

4.  Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.

Authors:  Eli L Diamond; Lorenzo Dagna; David M Hyman; Giulio Cavalli; Filip Janku; Juvianee Estrada-Veras; Marina Ferrarini; Omar Abdel-Wahab; Mark L Heaney; Paul J Scheel; Nancy K Feeley; Elisabetta Ferrero; Kenneth L McClain; Augusto Vaglio; Thomas Colby; Laurent Arnaud; Julien Haroche
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

Review 5.  Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature.

Authors:  Alessandro Broccoli; Vittorio Stefoni; Luca Faccioli; Claudio Agostinelli; Luca Spinardi; Marco Pastore Trossello; Pier Luigi Zinzani
Journal:  Rheumatol Int       Date:  2011-07-23       Impact factor: 2.631

Review 6.  Erdheim-Chester disease.

Authors:  Julien Haroche; Laurent Arnaud; Fleur Cohen-Aubart; Baptiste Hervier; Frédéric Charlotte; Jean-François Emile; Zahir Amoura
Journal:  Curr Rheumatol Rep       Date:  2014-04       Impact factor: 4.592

7.  Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.

Authors:  Dmitry Evseev; Irina Kalinina; Elena Raykina; Daria Osipova; Zalina Abashidze; Anna Ignatova; Anna Mitrofanova; Alexey Maschan; Galina Novichkova; Michael Maschan
Journal:  Int J Hematol       Date:  2021-08-12       Impact factor: 2.490

8.  A case of erdheim-chester disease with asymptomatic renal involvement.

Authors:  Hyun Jung Lee; Kyoung Yul Lee; Dong-Yeop Shin; Yun Gyoo Lee; Se Youn Choi; Kyung Chul Moon; Il-Kyu Han; Tae Min Kim
Journal:  Cancer Res Treat       Date:  2012-06-30       Impact factor: 4.679

9.  Dasatinib induces a dramatic response in a child with refractory juvenile xanthogranuloma with a novel MRC1-PDGFRB fusion.

Authors:  Shaimaa S Eissa; Michael R Clay; Teresa Santiago; Gang Wu; Lu Wang; Barry L Shulkin; Jennifer Picarsic; Kim E Nichols; Patrick K Campbell
Journal:  Blood Adv       Date:  2020-07-14

10.  Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report.

Authors:  Charalampos Tzoulis; Thomas Schwarzlmüller; Ivar Otto Gjerde; Eirik Søfteland; Gesche Neckelmann; Martin Biermann; Julien Haroche; Oddbjørn Straume; Olav Karsten Vintermyr
Journal:  BMC Res Notes       Date:  2015-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.